Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with psoralen plus ultraviolet A1

Abdel-Naser, Mohamed Badawy; El‐Khateeb, E. A.; Sallam, T.; Habib, M. Hadj

doi:10.1111/j.1365-2230.2006.02148.x

Cited by 12 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitiligo, a significantly lower expression of GM‐CSF, SCF, and bFGF have been found compared with partially affected or unaffected skin (Moretti et al., 2002). UVR increases the number of residual melanocytes most probably by enhancing melanocyte growth factors such as bFGF and endothelin‐1 (ET‐1) (Abdel‐Naser et al., 2006; Hirobe, 2005) . The activation of stem cells in the hair follicle and interfollicular epidermis, ‐which could escape the immune destruction mechanisms since they do not express melanocyte differentiation markers‐, could provide differentiated melanocytes for repigmentation (Osawa et al., 2005).…”

Section: Medical Therapymentioning

confidence: 99%

Update on skin repigmentation therapies in vitiligo

Falabella

Barona

2009

Pigment Cell Melanoma Res

137

121

View full text Add to dashboard Cite

SummaryTreatment for vitiligo is difficult and prolonged. Nevertheless, at present considerable knowledge accumulated during several decades on the pathogenic mechanisms, revealed important clues for designing new strategies to improve vitiligo depigmentation. With available medical therapies, high repigmentation percentages mostly on facial and neck lesions are achieved, although they are less effective on trunk and limbs and poor on the acral parts of the extremities. Narrow band UVB and psoralens and UVA are the two most important treatments for generalized vitiligo affecting more than 10-20% of the cutaneous surface, and topical corticosteroids, or calcineurin inhibitors are the most valuable treatments for localized vitiligo. Persistence of achieved regimentation is variable and an undefined percentage of patients may have variable recurrence.When vitiligo becomes refractory, surgical methods may improve depigmentation as effectively as with medical therapy; in segmental (unilateral) or long standing, non-segmental (bilateral) stable vitiligo, repigmentation with surgical methods is usually permanent.

show abstract

Section: Medical Therapymentioning

confidence: 99%

Update on skin repigmentation therapies in vitiligo

Falabella

Barona

2009

Pigment Cell Melanoma Res

137

121

View full text Add to dashboard Cite

show abstract

“…The clinical efficacy of NB‐UVB is partially due to its immunomodulating effects, which halt melanocytes' destruction, and so stop depigmentation. Yet, the main mechanism of its action is enhancing the process of repigmentation by stimulating melanocytes differentiation, migration and proliferation most probably by enhancing melanocyte growth factors such as basic fibroblast growth factor (bFGF) and endothelin‐1 (EN‐1) 17 . Indeed, Awad 18 previously demonstrated that NB‐UVB in vitiligo skin induces proliferation and migration of amelanotic spindle cells, as melanocyte precursors, to repopulate the epidermis with new generations of melanocytes restoring the pigmentation.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect of narrow band‐ultraviolet B on the expression of tyrosinase, TYRP ‐1, and TYRP ‐2 mRNA in vitiligo skin and their correlations with clinical improvement: A retrospective study

Awad

Moftah

Rashed

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Narrowband‐ultraviolet B (NB‐UVB) is considered one of the main therapeutic tools in vitiligo, which is able to induce repigmentation and halt depigmentation. However, little remains known about the effect of NB‐UVB on TYR gene family, the main pigmentary genes, in vitiligo patients. To assess the effect of NB‐UVB on expression of some genes related to the pigmentary problem of vitiligo; tyrosinase (TYR), tyrosinase related protein 1 (TYRP1) and tyrosinase related protein 2 (TYRP2), mRNA levels of those genes were quantitatively evaluated by Real‐Time quantitative Polymerase Chain Reaction (RT‐qPCR) in skin biopsies obtained from 30 patients with nonsegmental vitiligo and five healthy controls. Vitiligo patients were classified into two groups; group 1, involving 12 untreated vitiligo patients and group 2, including 18 vitiligo patients treated by NB‐UVB. The levels of TYR, TYRP‐1, and TYRP‐2 mRNAs in untreated group were significantly lower than in control subjects (P < .001). In NB‐UVB treated group, the three genes were significantly higher than in group 1 (P < .001), however, they were still significantly lower than in the control subjects (P < .001). A significant positive correlation was detected between TYR and TYRP‐2 genes in group 2 (P = .03). This study demonstrated that mRNA level of TYR, TYRP‐1, and TYRP‐2, which decreased in vitiligo, was significantly increased upon treatment with NB‐UVB. Accordingly, the mechanism of depigmentation in vitiligo disease and repigmentation by NB‐UVB treatment may be related to the changes in the expression of these genes.

show abstract

“…[ 8 ] Furthermore, EDN1 was found to be increased in patients undergoing PUVA treatment indicating a role of this peptide in vitiligo pathogenesis. [ 19 ] Besides, EDN1 is a strong vasoconstrictive agent which may contribute to controlling the inflammatory process seen in vitiligo. Indeed, blocking the EDN1/EDNRA signaling resulted in the loss of pigmentation in vivo .…”

Section: Discussionmentioning

confidence: 99%

The evaluation of endothelin-1 and endothelin receptor type a gene polymorphisms in patients with vitiligo

et al. 2016

View full text Add to dashboard Cite

Background:Endothelin-1 (EDN1) and EDN receptor type A (EDNRA) are implicated in melanocyte functions.Aim and Objectives:This study examines the role of EDN1 (G5665T and T-1370G) and EDNRA (C + 70G and G-231A) polymorphisms as a risk factor for vitiligo, and evaluates the relationship between genotypes and clinical characteristics of vitiligo patients.Materials and Methods:We analyzed genotype/allele distributions of EDN1 and EDNRA polymorphisms in 100 patients with vitiligo and 185 healthy controls by real-time polymerase chain reaction.Results:There was no notable risk for vitiligo afflicted by studied polymorphisms. However, the presence of EDNRA +70 variant G allele was found to be related with decreased risk for development of generalized type of vitiligo (odds ratio [OR]: 0.42, 95% confidence interval [CI] = 0.21–0.86, pcorr = 0.03) and showed protective effect against associated diseases seen in vitiligo (OR: 0.49, 95% CI = 0.27–0.88, pcorr = 0.034). Haplotype analysis demonstrated a strong (disequilibrium coefficient = 0.73, r2 = 0.405) linkage disequilibrium between EDN1 G5665T and T-1370G polymorphisms. The EDN1 5665/-1330 TT haplotype was over represented significantly in controls than in patients (P = 0.04).Conclusion:The studied polymorphisms do not seem to be a major risk for vitiligo. Haplotype analysis denoting protective effects against vitiligo may indicate an indirect interaction in the course of vitiligo. In addition, EDNRA + 70 polymorphism is protective against generalized type of vitiligo and associated diseases.

show abstract

Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with psoralen plus ultraviolet A1

Abstract: Systemic PUVA therapy in vitiligo may have a generalized mitogenic effect on melanocytes through the release of ET-1 into the circulation.

Cited by 12 publications

References 21 publications

Update on skin repigmentation therapies in vitiligo

Update on skin repigmentation therapies in vitiligo

Evaluation of the effect of narrow band‐ultraviolet B on the expression of tyrosinase, TYRP ‐1, and TYRP ‐2 mRNA in vitiligo skin and their correlations with clinical improvement: A retrospective study

The evaluation of endothelin-1 and endothelin receptor type a gene polymorphisms in patients with vitiligo

Contact Info

Product

Resources

About